论文部分内容阅读
目的前列腺特异性抗原(PSA)是检测前列腺癌和鉴别前列腺增生与前列腺癌的重要指标,近年来前列腺特异性抗原相关指标游离PSA(fPSA)与总PSA(tPSA)及fPSA/tPSA的应用极大提高了前列腺癌的诊断率。由于tPSA、fPSA测定值的高低与测定方法密切相关,不同的方法会导致不同的结果。我们采用电化学发光免疫分析技术对其进行测定,从而找出血清中tPSA检测值在4～10ng/ml之间的前列腺增生和前列腺癌患者fPSA/tPSA比值的临界值,为临床诊断前列腺癌提供依据。方法采用Roche Elecsys E170电化学发光免疫检测仪,分别测定其tPSA、fPSA,计算fPSA/tPSA的比值。结果前列腺癌与前列腺增生相比fPSA/tPSA的比值明显减低,差异有统计学意义(P<0.01)。结论使用电化学发光免疫试剂时以<0.15作为fPSA/tPSA临界值,为前列腺癌早期发现、监测及预后提供可靠的诊断依据。
Objective Prostate-specific antigen (PSA) is an important indicator of prostate cancer and differential diagnosis of prostatic hyperplasia and prostate cancer. In recent years, prostate-specific antigen-related indicators free PSA (fPSA) and total PSA (tPSA) and fPSA / tPSA Improve the diagnosis of prostate cancer. As tPSA, fPSA measured values ?? are closely related with the determination of the method, different methods will lead to different results. We use electrochemiluminescence immunoassay to determine the threshold of fPSA / tPSA ratio in patients with prostatic hyperplasia and prostate cancer with tPSA detected in serum of 4 ~ 10ng / ml, so as to provide the clinical diagnosis of prostate cancer in accordance with. Methods Roche Elecsys E170 electrochemiluminescence immunoassay was used to determine the ratio of tPSA and fPSA to fPSA / tPSA respectively. Results The ratio of fPSA / tPSA in prostate cancer was significantly lower than that in benign prostatic hyperplasia (P <0.01). Conclusion The electrochemiluminescence immunoassay using <0.15 as the critical value for fPSA / tPSA provides a reliable diagnostic basis for the early detection, monitoring and prognosis of prostate cancer.